<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03736317</url>
  </required_header>
  <id_info>
    <org_study_id>MZhao-009</org_study_id>
    <nct_id>NCT03736317</nct_id>
  </id_info>
  <brief_title>Transcranial Magnetic Stimulation for Treatment of Methamphetamine Use Disorder</brief_title>
  <official_title>Evaluation of the Effect of Repetitive Transcranial Magnetic Stimulation in Craving in Methamphetamine Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Repetitive transcranial magnetic stimulation (rTMS) was used to treat methamphetamine use
      disorder in previous studies, while the evidence-based protocols still required. The aim of
      this research is to develop more applicable rTMS intervention pattern and protocols to reduce
      craving and relapse of methamphetamine-dependent patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The limbic circuit and executive control circuit are two important frontal-striatal neural
      circuits associated with drug dependence. Previous studies showed increased functional
      activity within the limbic neural circuit (e.g. medial prefrontal cortex (mPFC) and ventral
      striatum) in the presence of a salient cue and decreased activity in the executive control
      circuit (e.g. dorsal prefrontal cortex and dorsal striatum). TMS was used to reverse the
      activities of these two circuits, by using continuous TBS and intermittent TBS, respectively.
      In this study, vmPFC cTBS was conducted to modulating the limbic circuit, while left dlPFC
      iTBS was conducted to modulating the executive control circuit. Combined treatment of vmPFC
      cTBS and left dlPFC iTBS was conducted to modulating two circuits simultaneously. Focused on
      evaluating the efficacy of the interventions and investigate the mechanisms,
      neuropsychological tests, biochemical tests, and electroencephalography will be used to
      investigate the neurobiological mechanism of the methamphetamine use disorder, craving, and
      relapse. The study will be very helpful to develop evidence-based rTMS protocols for
      methamphetamine-dependent patients in clinical practice and decrease harm for both the
      patients and their families.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Craving assessed by Visual Analog Scale</measure>
    <time_frame>12 months.</time_frame>
    <description>evaluate all participants' craving for for methamphetamine assessed by Visual Analog Scales (VAS). Score of VAS range from 0 to 10, and higher values represent high level of craving.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who relapse</measure>
    <time_frame>12 months</time_frame>
    <description>Follow up with patients after discharge, evaluate number of participants who relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression status assessed by Patient Health Questionnaire-9(PHQ-9)</measure>
    <time_frame>12 months</time_frame>
    <description>evaluate all participants' depression status by Patient Health Questionnaire-9(PHQ-9), PHQ-9 range from 0 to 27, and higher values represent more severe level of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety status assessed by Generalized Anxiety Disorder Screener (GAD-7)</measure>
    <time_frame>12 months</time_frame>
    <description>evaluate all participants' anxiety status by Generalized Anxiety Disorder Screener (GAD-7). PHQ-9 range from 0 to 21, and higher values represent more severe level of anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function assessed by CogState Battery (CSB)</measure>
    <time_frame>12 months</time_frame>
    <description>evaluate all participants' cognitive function by the computerized CogState Battery (CSB) Chinese version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response inhibition function</measure>
    <time_frame>12 months</time_frame>
    <description>assessed by Go nogo task under the electroencephalogram recording</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cue reactivity</measure>
    <time_frame>12 months</time_frame>
    <description>assessed by Cue reactivity task under the electroencephalogram recording</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Amphetamine Use Disorders</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham TBS delivered on left dlPFC or medial prefrontal cortex of amphetamine-dependent patients. Stimulation pulses are the same as the real group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>real mPFC cTBS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The real cTBS stimulation pattern will be delivered on the medial prefrontal cortex.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>real dlPFC iTBS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The real iTBS stimulation pattern will be delivered on the left dorsal prefrontal cortex.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>real dlPFC iTBS + real mPFC cTBS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy of real iTBS stimulation delivered on the left dorsal prefrontal cortex and real cTBS stimulation delivered on the medial prefrontal cortex.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham TBS</intervention_name>
    <description>Stimulate the dorsal lateral prefrontal cortex or medial prefrontal cortex for 2 weeks by sham Theta-burst stimulation (TBS), five times for a week with the sham coil.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>real mPFC cTBS</intervention_name>
    <description>Stimulate the medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.</description>
    <arm_group_label>real mPFC cTBS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>real dlPFC iTBS</intervention_name>
    <description>Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.</description>
    <arm_group_label>real dlPFC iTBS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>real dlPFC iTBS + real mPFC cTBS</intervention_name>
    <description>Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern, and stimulate medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.</description>
    <arm_group_label>real dlPFC iTBS + real mPFC cTBS group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In accordance with the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
             for methamphetamine (MA) use disorders

          -  Primary school degree or above

          -  Normal vision and hearing

          -  Dextromanual

          -  Less than one month before last drug use

        Exclusion Criteria:

          -  Have a disease that affect cognitive function such as history of head injury,
             cerebrovascular disease, epilepsy, etc

          -  Have cognitive-promoting drugs in the last 6 months

          -  Other substance abuse or dependence in recent five years (except nicotine)

          -  Mental impairment, Intelligence Quotient (IQ) &lt; 70

          -  Mental disorders

          -  Physical disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Zhao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Zhao, PhD</last_name>
    <phone>021-54252689</phone>
    <email>18017311005@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Min Zhao</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Compulsory Rehabilitation Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201900</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daqing Shi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amphetamine-type stimulants</keyword>
  <keyword>prefrontal-striatal circuits</keyword>
  <keyword>rTMS</keyword>
  <keyword>individualized therapy</keyword>
  <keyword>craving</keyword>
  <keyword>relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

